Jincheng Pharm: Subsidiary receives approval notice for drug supplementary application

Jincheng Pharm announced that its subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. This approval involves changes to the types and quantities of excipients, processes, and quality standards for Progesterone cream. According to IMS data, the global sales of Progesterone formulations are projected to be USD 78.0961 million, USD 94.3352 million, and USD 104 million from 2022 to 2024, respectively. The approval of this supplement application will help enhance product competitiveness but will not have a significant impact on current performance